EC ever use among women of reproductive age: 1.1% (DHS 2007)
EC knowledge among women of reproductive age: 18.8% (DHS 2013-14)
Contraceptive Use: 19.4% (DHS 2007, ever use of any modern method among women of reproductive age)
Registered LNG-EC products:
- Aleze EC* - Available only with prescription
- G-Nancy - Available only with prescription
- Levonorgestrel Richter* - Available only with prescription
- NorLevo 1.5mg* - Available only with prescription
- Pilule S - Available only with prescription
- Planfam - Available only with prescription
- Revoke 1.5* - Available only with prescription
- Revoke 72* - Available only with prescription
- Secufem - Available only with prescription
Products marked with * have been approved by a stringent regulatory authority, such as the WHO Prequalification Programme, the US Food and Drug Administration, the European Medicines Agency, or other.
Where at least one type of ECP is available: Public sector clinics, Pharmacies, IPPF-affiliated system
Age restrictions for accessing ECPs: No data available
Legal/regulatory documents in which EC is included: Essential Medicines List
Pricing information: In Kinshasa, the median price of LNG EC in the public sector is $1.43 and the median price of LNG EC in the private sector is $1.21, as of September 2016. In Katanga, the median price of LNG EC in the public and private sectors is $3.30, as of September 2016.
Other relevant information: EC distributed via IPPF outlets (1,000 - 5,000 in 2012).
1% of married contraceptive users and 4% of unmarried sexually active contraceptive users used EC in 2014 in the DRC according to PMA2020 data.
EC is not included in the National Strategic Plan for Family Planning (2014-2020).
For more information, see below: